Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study

• DOI: 10.3389/fonc.2021.630136
• Publication Date: 2021-03-23T06:39:31Z
• Authors: Kenji Morimoto; Tadaaki Yamada; Chieko Takumi; Yuri Ogura; Takayuki Takeda; Keisuke Onoi; Yusuke Chihara; Ryusuke Taniguchi; Takahiro Yamada; Osamu Hiranuma; Yoshie Morimoto; Masahiro Iwasaku; Yoshiko Kaneko; Junji Uchino; Koichi Takayama
• Keywords: Univariate analysis

The immunotherapy plus chemotherapy combination is one of the most promising treatments in advanced non-small-cell lung cancer (NSCLC). Immunotherapy often causes immune-related adverse events (irAEs), which have been reported to be associated with good clinical outcomes. However, effects remain unknown. In this study, we investigated association between irAEs caused by and efficacy patients NSCLC.We retrospectively analyzed data NSCLC, who received a at six institutions Japan January 2019 September 2019. We examined effect on various outcomes.We included 70 NSCLC. Patients were divided into two groups: without irAEs. had significantly longer progression-free survival than those univariate (hazard ratio 0.53, 95% confidence interval 0.30-0.93, p = 0.026) multivariate 0.29-0.97, 0.041) analyses. addition, grade 1-2 (mild irAEs) overall 3-5 (severe or (398 days versus 189 days, respectively; 0.0061) (not reached 412 0.021) analyses.Patients NSCLC experienced mild showed better response treatment severe Further large-scale research warranted confirm these findings.